Lifshitz M.,Medical Corps |
Lifshitz M.,Ben - Gurion University of the Negev |
Dwolatzky T.,Ben - Gurion University of the Negev |
Dwolatzky T.,Clalit Health Services |
And 4 more authors.
Journal of Geriatric Psychiatry and Neurology | Year: 2012
Introduction: The English version of the Montreal Cognitive Assessment (MoCA) test has been shown to be reliable in screening for mild cognitive impairment (MCI). However, the sensitivity and specificity of the Hebrew version of this instrument are yet to be determined. Methods: The study population consisted of 2 groups of older individuals, 74 patients diagnosed with MCI and 80 patients who were cognitively asymptomatic. Cognitive evaluation included the Mini-Mental State Examination (MMSE), Mindstreams computerized cognitive assessment, and the MoCA test. Results: The Hebrew version of MoCA distinguished between cognitively asymptomatic older individuals and those with MCI, with a sensitivity of 94.6% and a specificity of 76.3%, using a cutoff of 26/30 points. Conclusions: The Hebrew version of the MoCA test is effective for identifying MCI in older patients. As a screening instrument for MCI, its higher sensitivity makes it preferable o the MMSE, which is used extensively in the clinical setting. © The Author(s) 2012.
News Article | February 15, 2017
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NASDAQ: AIQ) (the “Company”, “Alliance”, “we” or “our”), a leading national provider of outsourced radiology, oncology and interventional services, announced today that Gregg Alan Dickerson, M.D., FACR, FACRO, has joined Alliance Cancer Centers in Greenville and Clarksdale and will be offering radiation oncology services to patients throughout Greenville, Clarksdale and the surrounding communities. “We are pleased to have Dr. Dickerson join the medical staff of the Alliance Cancer Centers in Greenville and Clarksdale,” said Candi Underwood, Site Administrator for the Alliance Cancer Centers in Greenville and Clarksdale. “Dr. Dickerson is a highly accomplished physician who brings over thirty years of radiation oncology experience to our cancer care treatment team and we are fortunate to have him care for the patients in our centers.” Gregg Alan Dickerson, M.D., FACR, FACRO, is a board certified radiation oncologist. Dr. Dickerson received his Bachelor of Arts with a double major in chemistry and biology from Indiana University in Bloomington, Indiana, and his medical degree from Indiana University School of Medicine in Indianapolis, Indiana. He completed his residency training in radiation oncology at the Bodine Center for Cancer Treatment at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, where he also served as Chief Resident. In addition to his education and medical training, Dr. Dickerson spent 11 years serving our country as a flight surgeon in the Medical Corps of the Air National Guard, becoming a Major before being honorably discharged in 1996. Dr. Dickerson joined the Alliance Cancer Centers in Greenville and Clarksdale last October as an interim physician. “After many rewarding and productive years in Denver, Colorado, where I became highly specialized and accomplished for my work treating prostate cancer with radiosurgery, it was time to get ready for the next phase of my career,” said Dickerson. “It was at that time colleagues in the leadership of Alliance Oncology encouraged me to come to Mississippi to spend some time helping the good people of the Delta. What started off as a commitment for just a few months turned into a desire to continue caring for the dear people here and face the challenges that the spectrum of cancers they develop present. Joining the many other very compassionate physicians in the Delta and employing my advanced skills has been extremely satisfying and ultimately led to wanting to continue my work here.” Dr. Dickerson has been awarded over ten specialty honors and peer selected honors, including being ranked the number one radiation oncologist in Colorado in 2014 by HealthGrades.com. He also holds both military and civilian honors. He is a member of the American Society of Therapeutic Radiologists and Oncologists (ASTRO), the American College of Radiology (ACR), the American College of Radiation Oncology (ACRO), the Colorado Radiological Society, and the CyberKnife Society. For more information on Dr. Dickerson, or to schedule an appointment, please visit www.alliance-greenville-clarksdale.com. Alliance HealthCare Services (NASDAQ: AIQ) is a leading national provider of outsourced healthcare services to hospitals and providers. We also operate freestanding outpatient radiology, oncology and interventional services clinics, and Ambulatory Surgical Centers (“ASC”) that are not owned by hospitals or providers. Diagnostic radiology services are delivered through the Radiology Division (Alliance HealthCare Radiology), radiation oncology services are delivered through the Oncology Division (Alliance Oncology), and interventional and pain management services are delivered through the Interventional Division (Alliance Interventional). Alliance is the nation’s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide. As of September 30, 2016, Alliance operated 619 diagnostic radiology and radiation therapy systems, including 112 fixed-site radiology centers across the country, and 32 radiation therapy centers and SRS facilities. With a strategy of partnering with hospitals, health systems and physician practices, Alliance provides quality clinical services for over 1,000 hospitals and other healthcare partners in 45 states, where approximately 2,400 Alliance Team Members are committed to providing exceptional patient care and exceeding customer expectations. For more information, visit www.alliancehealthcareservices-us.com.
News Article | November 18, 2016
YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that an abstract highlighting the merits of NexoBrid® in the management of burns in mass casualty incidents was selected as “Best Poster” at the International Disaster and Military Medicine (DiMiMED) 4th Annual Conference, held November 15-16 in Dusseldorf, Germany. The poster, titled “The role of rapid & effective enzymatic debridement/escharotomy in burn mass casualties' incidents,” was delivered by Prof. Lior Rosenberg, MediWound's Chief Medical Officer and former head of the International Society of Burn Injury disaster committee. The prize was awarded by the co-chairmen of the conference, Dr. Christoph Büttner, MC Dr, Rear Admiral uh (ret), Editor-in-chief of Medical Corps International Forum, Germany and Dr. Rob van der Meer, MD, Brigadier General (ret), Former Surgeon General of the Netherlands Armed Forces. The poster highlights how NexoBrid's debridement and enzymatic escharotomy can reduce surgical burden, dependency on highly trained surgeons and scarce surgical facilities. NexoBrid provides rapid and selective, nonsurgical removal of the eschar at the patient's bedside, resolves or possibly prevents Burn Induced Compartment Syndrome (BICS), which currently requires immediate surgical intervention, and enables early visual diagnosis of burn severity. Collectively these contribute to increased surge capacity, and possibly reduced mortality and morbidity as well as faster resilience. “We are delighted that the role of NexoBrid in the management of mass casualty incidents continues to be acknowledged by thought-leading organizations such as the DiMiMED and the International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters. Recognition has also come from important government agencies and officials such as the U.S. Biomedical Advanced Research and Development Authority and the president and government officials of Romania, following the Colectiv nightclub disaster,” noted Gal Cohen, President and Chief Executive Officer of MediWound. "Unfortunately, mass casualty incidents are not limited to acts of war or urban terror. There are civilian mass casualties as we have seen recently with the explosions at a Chinese chemical plant, and at an amusement park in Taiwan, each of which resulted in hundreds of burn victims. Even a multivehicle road accident could challenge burn treatment capacity and turn into a mass casualty incident. We look forward to working with various international agencies and with governments to advance the use of NexoBrid for mass casualty and disaster preparedness, as well as in military medicine,” added Mr. Cohen. According to Prof. Rosenberg, "Burn Induced Compartment Syndrome is characterized by severe high pressure in the compartment, which results in insufficient blood supply to muscles and nerves. It is a medical emergency that requires immediate surgical intervention. On one hand, if left untreated, the lack of blood supply leads to permanent muscle and nerve damage and can result in the loss of limb function. On the other hand, if escharotomy is not done by highly trained personnel, it could result in permanent damage to vital structures such as nerves and tendons, leading to impaired long-term functionality and permanent long linear scars. “During the NexoBrid Phase 3 study, no escharotomies were done in deeply burned hands treated with NexoBrid, versus 9.8% in deeply burned hands treated by standard of care. In fact, during NexoBrid’s clinical development more than 130 extremities treated with NexoBrid did not require escharotomies,” added Prof. Rosenberg. “This is imperative in the management of mass casualty incidents as extremities are the most frequently burned area, and if deeply burned are most likely to develop BICS. Not only can NexoBrid rapidly remove eschar and allow burn severity diagnosis, but it may avoid the need for immediate escharotomy. It is important to note that in routine burn care as well, surgical debridement and escharotomy are among the most traumatic surgical procedures and are challenging for both the care provider and patient. As demonstrated, NexoBrid nonsurgical debridement can significantly reduce such surgical burden.” DiMiMED is the International Conference on Disaster and Military Medicine focussing on current issues in military medicine and disaster medicine. The disasters taking place all over the world have shown that it is absolutely essential for civilian medical services and the military medical services to join forces to provide optimum on-site medical care. In addition to civilian medical services, the medical services of the armed forces are increasingly used to deal with disasters. DiMiMED provides a platform for exchanging experiences, holding discussions and for promoting global cooperation. The DiMiMED conference is organized by the Beta Group / Beta Verlag & Marketinggesellschaft mbH, under the auspices of the Medical Corps International Forum and powered by MEDICA / Messe Düsseldorf GmbH. NexoBrid is an easy-to-use, topically-applied product that removes dead or damaged tissue, known as eschar, in approximately four hours without harming the surrounding healthy tissues. NexoBrid received marketing authorization from the European Medicines Agency for the removal of eschar in adults with deep partial and full-thickness thermal burns, is commercially available in Europe and Israel and will be launched in Argentina in the coming months. Representing a new paradigm in burn care management, NexoBrid demonstrated in clinical studies, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier than other modalities, without harming viable tissues. The removal of eschar or “debridement” is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. With the current standard of care, burn eschar is removed either with existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue necessitating further surgical treatments. The U.S. Phase 3 clinical trial and registration process for NexoBrid is being funded in whole or in part with federal funds under a contract with the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority. MediWound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound’s first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency as well as the Israeli and Argentinian Ministries of Health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe and Israel, with plans for a launch in Argentina. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. MediWound's second innovative product, EscharEx® is a topical biological drug being developed for debridement of chronic and other hard-to-heal wounds and is complementary to the large number of existing wound healing products, which require a clean wound bed in order to heal the wound. EscharEx® contains the same proteolytic enzyme technology as NexoBrid®, and benefits from the wealth of existing development data on NexoBrid®. In two Phase 2 studies, EscharEx® has demonstrated safety and efficacy in the debridement of chronic and other hard-to-heal wounds, within a few daily applications. For more information, please visit www.mediwound.com. This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to the regulatory authorizations and launch dates. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on MediWound’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. In particular, you should consider the risks discussed under the heading “Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2015 and information contained in other documents filed with or furnished to the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. The forward-looking statements made herein speak only as of the date of this announcement and MediWound undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
News Article | November 16, 2016
JACKSON, MS, November 16, 2016-- Dr. Richard D. deShazo has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.Dr. deShazo's busy career has included service as a practicing medical consultant, educator, researcher and academic administrator; public broadcasting producer and on air host; and author. Born in Birmingham, Ala. in 1945, he earned a Bachelor of Arts in chemistry and religion from Birmingham Southern College before attaining an MD at the University of Alabama in 1971. Dr. deShazo then completed an internship in pediatrics, a residency in internal medicine, a fellowship in immunology and microbiology, and a fellowship in clinical immunology. He further prepared for his career by becoming board-certified by the American Board of Internal Medicine, the American Board of Allergy and Immunology, the American Board of Rheumatology, the American Board of Geriatrics and the National Board of Medical Examiners. He has published over 300 original scientific articles in peer reviewed literature.Having completed a residency and fellowships at the Walter Reed Army Medical Center, Dr. deShazo spent eight years in the U.S. Army Medical Corps reaching the rank of lieutenant colonel. He was awarded the Distinguished Service Medal by the Department of the Army. He also began his career as a medical educator, starting as a clinical assistant professor of medicine at the University of Colorado School of Medicine. He was then an assistant professor of medicine and pediatrics at the Uniformed Services University of the Health Sciences before spending nine years with Tulane University School of Medicine. While at Tulane, Dr. deShazo advanced from associate professor to full professor of medicine and pediatrics, and also served as vice chair of clinical operations. In 1989, he left Tulane University to become a professor and chairman of the Department of Medicine at the University of South Alabama College of Medicine. After eight years in this role, he accepted the position of professor of medicine and pediatrics and chairman of the Department of Medicine at the University of Mississippi Medical Center. He stepped down from his chairman role in 2010, but he continues to teach at the university as a Billy S. Guyton Distinguished Professor of medicine and pediatrics.In addition to teaching, Dr. deShazo has been a producer of radio and television health documentary programming for Mississippi Public Broadcasting since 2010. As such, he leads a daily radio series called "Southern Remedy," during which experts discuss current and relevant health issues and topics. The program can be heard on Mississippi Public Broadcasting's Think Radio from 11 am until noon, as well as online at http://www.mpbonline.org/programs/radio/listen-live . He was associate editor of the Southern Medical Journal from 1995 to 2013. He now serves as an associate editor of the American Journal of Medicine and is on the editorial boards of numerous medical journals.Dr. deShazo has remained an active member of the medical community through affiliations with the American College of Physicians, the American College of Rheumatology, the American College of Chest Physicians, and the American Academy of Allergy, Asthma and Immunology, among numerous other organizations. He was elected a Master of the American College of Physicians and a Distinguished Fellow of the American College of Allergy, Asthma and Immunology. He has taken on a number of leadership roles within these organizations and has received formal honors from them as well. Some of his most recent honors include a 2015 Southeast Emmy Award nomination and a 2015 and 2016 Telly Award for his work on "Southern Remedy." In 2013, he received the Mississippi Humanities Council Commercial Media Award, as well as media and communication awards from the Association of American Medical Colleges. He also received the Martha Meyers Physician Role Model Award from the University of Alabama School of Medicine. Dr. deShazo and his wife, Gloria, have 3 children and 6 grandchildren. Dr. deShazo has been featured in the 59th through 70th editions of Who's Who in America, the 7th and 8th editions of Who's Who in American Education, the 2nd through 8th editions of Who's Who in Medicine and Healthcare, the 11th and 12th editions of Who's Who in Science and Engineering, the 27th through 42nd editions of Who's Who in the South and Southwest, and the 26th through 33rd editions of Who's Who in the World.About Marquis Who's Who :Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America , Marquis Who's Who has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Today, Who's Who in America remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis now publishes many Who's Who titles, including Who's Who in America , Who's Who in the World , Who's Who in American Law , Who's Who in Medicine and Healthcare , Who's Who in Science and Engineering , and Who's Who in Asia . Marquis publications may be visited at the official Marquis Who's Who website at www.marquiswhoswho.com
Gross R.,Myers JDC Brookdale Institute |
Gross R.,Bar - Ilan University |
Brammli-Greenberg S.,Myers JDC Brookdale Institute |
Rabinowitz J.,Bar - Ilan University |
And 3 more authors.
International Journal of Pediatric Obesity | Year: 2011
Objective. To analyze the temporal trends of obesity over time among male adolescents of different ethnic origins. Methods. Population-based national data of subjects presenting at recruitment centers for medical examinations as part of screening for military draft. Subjects were 17-year-old Jewish males (n=1 140 937) born in the years 19501986. Data on body mass index (BMI) were measured (without clothing and shoes) by physicians. We calculated the prevalence of obesity (BMI 29.4 or higher) for each year by ethnic origin group. A Multinomial logistic regression model was used to estimate the effects of ethnic origin and other risk factors on the likelihood of obesity. Results. Over time, obesity rates have risen among all ethnic groups of adolescents. Multinomial regression analysis showed a lower likelihood of obesity among those of Asia-Africa origin as compared with other groups. However, obesity rates have increased more significantly over time among this ethnic group compared with the other groups. Conclusion. A significant finding of this study is the disparities in temporal trends in the likelihood of obesity over time. Among adolescents of Asia-Africa origin the likelihood of obesity increased more steeply over time compared with other groups of adolescents. Health services in Israel should thus consider Asia-African origin as a distinct risk factor and target interventions to prevent future obesity among these adolescents. © 2011 Informa Healthcare.
PubMed | University of Kentucky, New York University, Wayne State University, Emory University and 6 more.
Type: Journal Article | Journal: Academic radiology | Year: 2015
Simulation is a promising method for improving clinician performance, enhancing team training, increasing patient safety, and preventing errors. Training scenarios to enrich medical student and resident education, and apply toward competency assessment, recertification, and credentialing are important applications of simulation in radiology. This review will describe simulation training for procedural skills, interpretive and noninterpretive skills, team-based training and crisis management, professionalism and communication skills, as well as hybrid and in situ applications of simulation training. A brief overview of current simulation equipment and software and the barriers and strategies for implementation are described. Finally, methods of measuring competency and assessment are described, so that the interested reader can successfully implement simulation training into their practice.
News Article | November 17, 2016
The Israel Defense Forces (IDF) Medical Corps received the first “Type 3” designation by the United Nations’ World Health Organization (WHO). At a ceremony last week, the Israeli field hospital, comprised of 30 medical shelters from Alaska Structures Inc., was described as “the number one in the world”. In the wake of a sudden onset disaster (SOD), the Type 3 designation will ensure the Israeli medical team and field hospital will continue to be the first allowed on the scene to provide emergency medicine and services. To earn the Type 3 designation, the IDF’s field hospital must have 40 inpatient beds, two operating rooms capable of performing 15 to 30 surgeries per day, and provide other services such as rehabilitation. The IDF field hospital far surpasses the Type 3 requirement, technically making it a “Type 3 Plus” system - is equipped with 86 inpatient beds, four operating rooms, and has the ability to carry out plastic surgery and OB/GYN care. 16 foreign medical teams (FMTs) have been awarded Type 1 or Type 2 designations by the WHO. The IDF Medical Corps is the only medical team and field hospital, with a military component to have been awarded the Type 3 designation. There are currently no other Type 3 classifications in the process of being verified, stated Dr. Ian Norton, the lead author of the classification system and Head of the WHO delegation. It is a “national treasure” that has the capabilities of an advanced, permanent hospital but can be setup almost anywhere in under 12 hours, stated its commander, Lt. Col. (res.) Dr. Ofer Merin. A formal ceremony being held in Hong Kong at the end of the month will award the IDF Medical Corps members with special patches. Helping other countries in need is “the most effective kind of diplomacy” stated former foreign minister Avigdor Liberman. Since 1999, Alaska Structures has provided more than 35,000 American-made military shelters and over 17,000 Environmental Control Units (ECU) to U.S. and other; Military Forces around the world.
PubMed | Chaim Sheba Medical Center, Medical Corps and Shaare Zedek Hospital
Type: Journal Article | Journal: Military medicine | Year: 2015
Tension pneumothorax is one of the leading causes of preventable death in trauma patients. Needle thoracotomy (NT) is the currently accepted first-line intervention but has not been well validated. In this review, we have critically discussed the evidence for NT procedure, re-examined the recommendations by the Advanced Trauma Life Support organization and investigated the safest and most effective way of NT. The current evidence to support the use of NT is limited. However, when used, it should be applied in the 2nd intercostal space at midclavicular line using a catheter length of at least 4.5 cm. Alternative measures should be studied for better prehospital management of tension pneumothorax.